Bo Hao
Impact in
- Cancer Research top 10%
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
-
- Immune cells in cancer
Papers in
-
- RNA modifications and cancer 4
-
- Ferroptosis and cancer prognosis 9
- Lung Cancer Diagnosis and Treatment 3
- Lung Cancer Treatments and Mutations 3
- Co-authors
- Qing Geng (20 shared papers)Wenyang Jiang (7 shared papers)Ruyuan He (7 shared papers)Heng Meng (6 shared papers)Weichen Lin (4 shared papers)Bohao Liu (6 shared papers)Zhihua Geng (2 shared papers)Ning Li (8 shared papers)
- Journals
- Frontiers in Pharmacology (2 papers)Oncotarget (2 papers)Frontiers in Immunology (2 papers)Heliyon (2 papers)Scientific Reports (2 papers)
- Partner nations
- ChinaUnited StatesSpain
In The Last Decade
Bo Hao
34 papers receiving 842 citations
Bo Hao's Hit Papers
Peers
Comparison fields: 5 of 88
- Cancer Research 147
- Immunology 154
- Pulmonary and Respiratory Medicine 207
- Infectious Diseases 122
- Oncology 140
Countries citing papers authored by Bo Hao
This map shows the geographic impact of Bo Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Hao more than expected).
Fields of papers citing papers by Bo Hao
This network shows the impact of papers produced by Bo Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Hao. The network helps show where Bo Hao may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Hao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Itaconate inhibits ferroptosis of macrophage via Nrf2 pathways against sepsis-induced acute lung injury Hit paper breakdown → | 2022 | 192 |
| 2 | 2020 | 187 | |
| 3 | 2021 | 76 | |
| 4 | 2022 | 62 | |
| 5 | 2022 | 53 | |
| 6 | 2024 | 33 | |
| 7 | 2018 | 27 | |
| 8 | 2018 | 25 | |
| 9 | 2022 | 21 | |
| 10 | 2020 | 17 | |
| 11 | 2018 | 15 | |
| 12 | 2021 | 14 | |
| 13 | 2023 | 13 | |
| 14 | 2019 | 13 | |
| 15 | 2022 | 12 | |
| 16 | 2022 | 12 | |
| 17 | 2019 | 9 | |
| 18 | 2020 | 7 | |
| 19 | 2020 | 6 | |
| 20 | 2022 | 6 |
About Bo Hao
Bo Hao is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Cancer Research and Immunology, having authored 36 papers that have together received 847 indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (9 papers), Cancer Immunotherapy and Biomarkers (9 papers), Cancer, Lipids, and Metabolism (4 papers), RNA modifications and cancer (4 papers), Immune cells in cancer (3 papers), Lung Cancer Diagnosis and Treatment (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer-related molecular mechanisms research (3 papers). The work is most often cited by research in Cancer Research (147 citations), Immunology (154 citations), Pulmonary and Respiratory Medicine (207 citations), Infectious Diseases (122 citations) and Oncology (140 citations). Bo Hao has collaborated with scholars based in China, United States and Spain. Frequent co-authors include Qing Geng, Wenyang Jiang, Ruyuan He, Heng Meng, Weichen Lin, Bohao Liu, Zhihua Geng, Ning Li, Rui Xiong and Tao Fan. Their work appears in journals such as Frontiers in Pharmacology, Oncotarget, Frontiers in Immunology, Heliyon and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.